Levofloksatsin (Tavanik) v lechenii vnebol'nichnoy pnevmonii u vzroslykh


Cite item

Full Text

Abstract

В отличие от большинства первых антибиотиков, имеющих природное происхождение (т.е. являющихся продуктами жизнедеятельности живых организмов) – пенициллинов, цефалоспоринов, макролидов и др., – прототипом хинолонов оказалось вещество, полученное путем химического синтеза. Отчасти анекдотичное открытие G.Lesher и соавт. в 1962 г. налидиксовой кислоты1 стало отправной точкой в создании уникальных и одних из наиболее клинически востребованных в настоящее время антибиотиков – хинолонов/фторхинолонов. Эволюция хинолонов сопровождалась расширением спектра антимикробной активности и, соответственно, перечня показаний для их клинического использования, улучшением фармакокинетических параметров и профиля безопасности препаратов. Каждое из пяти десятилетий применения хинолонов в медицинской практике было отмечено появлением на фармацевтическом рынке новых представителей этого класса антибиотиков).тические данные, доказывающие их очевидную терапевтическую привлекательность (непревзойденная эффективность, приемлемый профиль безопасности, сохранение высокой чувствительности ключевых респираторных патогенов), позволили выделить конкретные «целевые» группы пациентов (например, больные ВП с факторами риска терапевтической неудачи), у которых назначение РФ признавалось оптимальным. Одним из весомых аргументов в пользу их широкого применения у взрослых больных ВП является успешный и беспрецедентный по масштабам опыт использования прототипа всех РФ – левофлоксацина.

Full Text

Левофлоксацин (Таваник) в лечении внебольничной пневмонии у взрослых
×

About the authors

A. I Sinopal'nikov

References

  1. Lesher G.Y., Froelich E.D., Gruett M.D. et al. 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 1962; 5: 1063–8.
  2. Emmerson A.M., Jones A.M. The quinolones: decades of development and use. J Antimicrob Chemother 2003; 51 (Suppl. S1): 13–20.
  3. Naber K, Adam D. Expertengruppe der PEG. Einteilung der Fluorchinolone. Chemother J 1998; 7: 66–8.
  4. Langtry H.D., Lamb H.M. Levofloxacin: Its use in infections of respiratory tract, skin, soft tissues and urinary tract. Drugs 1998; 56: 487–515.
  5. National Committee for Clinical Laboratory Standars. Perfomance standards for antimicrobial susceptibility testing: twelfth informational supplement. V. 22 Wayne (PA); 2002. NCCLS document M100–S12.
  6. Lynch J.P., File T.M., Zhanel G.G. Levofloxacin for the treatment of community - acquired pneumonia. Expert Rev Anti Infect Ther 2006; 4: 725–42.
  7. Felmingham D, Feldman C, Hryniewicz W et al. Surveillance of resistance in bacteria causing community - acquired respiratory tract infections. Clin Microbiol Infect 2002; 8 (Suppl. 2): 12–42.
  8. Liu H.H. Safety Profile of the Fluoroquinolones. Focus one Levofloxacin. Drug Saf 2010; 33 (5): 353–69.
  9. Doern G.V., Richter S.S., Miller A et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41: 139–48.
  10. Doern G.V., Brown S.D. Antimicrobial susceptibility among community - acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000–2001. J Infect 2004; 48: 56–65.
  11. Noreddin A.M., W.F. Elkhatib. Levofloxacin in the treatment of community - acquired pneumonia. Expert Rev Anti Infect Ther 2010; 8: 505–14.
  12. Козлов Р.С., Сивая О.В., Кречикова О.И. и др. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. (Результаты многоцентрового проспективного исследования ПеГАС). Клин. микробиология и антимикроб. химиотерапия. 2010; 12 (4): 329–41.
  13. File T.M. Jr., Segreti J, Dunbar L et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community - acquired pneumonia. Antimicrob Agents Chemother 1997; 33: 1965–72.
  14. Norrby S.R., Petermann W, Willcox P.A. et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30: 397–404.
  15. Gotfried M.H., Dattani D, Riffer E et al. A controlled, double - blind, multicenter study comparing clarithromycin extended - release tablets and levofloxacin tablets in the treatment of community - acquired pneumonia. Clin Ther 2002; 24: 736–51.
  16. Frank E, Liu J, Kinasewitz G et al. A multicenter, open - label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community - acquired pneumonia. Clin Ther 2002; 24: 1292–308.
  17. Fogarty C, Siami G, Kohler R et al. Multicenter, open - label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin - clavulanate in the treatment of serious community - acquired pneumonia in adults. Clin Infect Dis 2004; 38: S16–S23.
  18. D’Ignazio J, Canere M.A., Lewis D.E. et al. Novel, single - dose microsphere formulation of azithromycin versus 7 - day levofloxacin therapy for treatment of mild to moderate community - acquired pneumonia. Antimicrob Agents Chemother 2005; 49: 4035–41.
  19. Dunbar L.M., Wunderick R.G., Habib M.P. et al. High - dose, short course levofloxacin for community - acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37: 752–60.
  20. Shorr A.F., Zadeikis N, Xiang J.X. et al. A multicenter, randomized, double - blind retrospective comparison of 5- and 10 - day regimens of levofloxacin in a subgroup of patients ≥65 years with community - acquired pneumonia. Clin Ther 2005; 27: 1251–9.
  21. Erard V, Lamy O, Bochud P.Y. et al. Full - course oral levofloxacin for treatment of hospitalized patients with community - acquired pneumonia. Eur J Clin Microbiol Infect Dis 2004; 23: 82–8.
  22. Leroy O, Saux P, Bedos J.P., Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community - acquired pneumonia who do not require vasopressors. Chest 2005; 128: 172–83.
  23. Anzueto A, Niederman M.S., Pearl J et al. Community - acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxofloxacin therapy versus that levofloxacin therapy. Clin Infect Dis 2006; 42: 73–81.
  24. Akpunonu B, Michaelis J, Uy C.N. et al. Multicenter, postmarketing assessment of levofloxacin in the treatment of adults with community - acquired pneumonia. Clin Infect Dis 2004; 38 (Suppl. 1): S5–S15.
  25. Marrie T.J., Lau C.Y., Wheeler S.L. et al. A controlled trial of a critical pathway for treatment of community - acquired pneumonia. CAPITAL study investigators. Community - acquired pneumonia intervention trial assessing levofloxacin. J Am Med Assos 2000; 283: 749–55.
  26. Yu V.L., Greenbery R.N., Zadeikis N et al. Levofloxacin efficacy in the treatment of community - acquired legionellosis. Chest 2004; 125: 2135–9.
  27. Blazquez Garrido R.M., Espinosa Parra F.J., Alemany Francis L et al. Antibacterial chemotherapy for legionnaries disease: levofloxacin versus macrolides. Clin Infect Dis 2005; 40: 800–6.
  28. Mykietiuk A, Carratal J, Fernandez-Sabe N et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 2005; 40: 794–9.
  29. Kahn J.B., Wiesinger A, Xiang J. Macrolide - resistance Streptococcus pneumoniae in community - acquired pneumonia: clinical and microbiological outcomes for patients treated with levofloxacin. Clin Infect Dis 2004; 38 (Suppl. 1): S24–S33.
  30. Olive D, Georges H, Devos P et al. Severe pneumococcal pneumonia: impact of new quinolones on prognosis. BMC Infect Dis 2011; 11: 66–73.
  31. Kuhn F, Cottagnoud M, Acosta F et al. Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin resistant pneumococci and prevents selection of levofloxacin - resistant mutants in vitro. Antimicrob Agents Chemother 2003, 47: 2487–91.
  32. Gimeno C, Boria J, Navarro D et al. In vitro interaction between ofloxacin and cefotaxime against grampositive and gramnegative bacteria involved in serious infections. Chemotherapy 1998, 44: 94–8.
  33. Ye X, Sikirica V, Schein J.R. et al. Treatment failure rates and health care utilization and costs among patients with community - acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin Ther 2008; 30: 358–70.
  34. Hess G, Hill J.W., Raut M.K. et al. Comparative antibiotic failure rates in the treatment of community - acquired pneumonia: results from a claims analysis. Adv Ther 2010; 27: 743–55.
  35. Vardakas K.Z., Siempos I.I., Grammatikos A et al. Respiratory fluoroquinolones for the treatment of community - acquired pneumonia: a meta - analysis of randomized controlled trials. Can Med Assoc J 2008; 179: 1269–77.
  36. Ball P. Role of levofloxacin in the treatment of lower respiratory tract infections. Penetration: New challenges for levofloxacin in the fight against infectious diseases. Annual Issue 2003. Tokyo: BIOMEDIS 2003: 22–32.
  37. Khashab M.M., Xiang J, Kahn J.B. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr Med Res Opin 2006; 22: 1997–2006.
  38. Tillotson G, Ball P. Fluoroquinolone safety profiles – A review. Today’s Therapeutic Trends 2002; 20: 419–35.
  39. Lipsky B.A., Baker C.A. Fluoroquinolone toxicity profiles: a review focusing on new agents. Clin Infect Dis 1999; 28: 352–64.
  40. Levaquin® (Levofloxacin tablets, oral solution, injection): US prescribing information. OrthoMcNeil Pharmaceutical, Inc., Raritan, Nj, USA, 2009.
  41. Thiem U, Heppner H.J., Pientka L. Elderly patients with community - acquired pneumonia. Optimal treatment strategies. Drugs Aging 2011; 28: 519–37.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-63969 от 18.12.2015. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 69134 от  24.03.2017.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies